Keenova Unveils Breakthrough Analysis on Terlipressin at ACG Annual Meeting
Keenova Unveils Breakthrough Analysis on Terlipressin at ACG Annual Meeting
Keenova Therapeutics plc has made headlines with its recent presentation regarding TERLIVAZ® (terlipressin) at the American College of Gastroenterology (ACG) Annual Meeting, which is taking place from October 9-14, 2026. This new analysis focuses specifically on hepatorenal syndrome-acute kidney injury (HRS-AKI), a complex, life-threatening condition associated with advanced liver disease. The data presented promises to enhance the medical community's understanding of this rapidly progressing health issue.
Understanding Hepatorenal Syndrome-Acute Kidney Injury
Hepatorenal syndrome-AKI is characterized by a swift decline in kidney function, significantly impacting patients with severe liver conditions. It poses high risks of morbidity and mortality, making timely intervention critical. The increase in hospitalizations for HRS-AKI, from around 42,930 patients in 2018 to an estimated 63,381 in 2023, highlights the growing prevalence and urgency of addressing this condition.
As noted by Dr. Nancy Reau, the Associate Director of Solid Organ Transplantation at Rush University Medical Center and the lead author of this presentation, “We are delighted to share these findings with our peers in the medical community, as they can substantially contribute to our comprehension of a challenging and often severe condition.” The exploratory analysis aims to provide clinical evidence on the use of terlipressin in patients who are ineligible for liver transplantation, a critical factor given the limited treatment options available for this population.
Insights from the Presentation
The presentation on October 12 is titled “Efficacy and Safety of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Ineligible for Liver Transplant: An Exploratory Analysis of the CONFIRM Trial.” The team of authors includes respected professionals such as Kavish Patidar, Laurie Larson, and several others, who collectively bring extensive expertise on HRS and related therapeutic approaches.
Terlipressin is currently recognized as the first and only FDA-approved therapy identified to improve kidney function specifically in adults diagnosed with HRS-AKI. This revolutionary treatment provides a vital non-surgical option for patients facing dire health situations where immediate intervention is paramount.
Safety Information and Usage Considerations
While the advantages of TERLIVAZ are promising, it is crucial to adhere to specific safety guidelines. Patients with a serum creatinine level exceeding 5 mg/dL may not benefit from terlipressin. Additionally, the treatment comes with significant warnings regarding the risk of serious or fatal respiratory failure. Thus, healthcare providers are advised to conduct thorough assessments on oxygen saturation prior to commencing terlipressin therapy and to monitor patients closely during treatment.
The presentation sheds light not just on the efficacy but also provides critical insights regarding potential adverse reactions. Symptoms such as abdominal pain, nausea, and respiratory issues are among the most common reactions clinicians should be aware of when prescribing terlipressin.
About Keenova Therapeutics
Headquartered in Dublin, Ireland, Keenova Therapeutics is dedicated to addressing complex medical conditions with innovative solutions. Committed to improving the lives of patients dealing with rare or unaddressed diseases, Keenova operates a robust manufacturing presence across the U.S., ensuring high-quality production and distribution of its therapeutics.
Exploring specialty areas of unmet need, including nephrology and hepatology, the company strives to amplify the conversation around potential improvements in healthcare treatments—especially conditions like HRS-AKI where treatment options have been historically limited.
For more information about Keenova's initiatives and therapeutic offerings, please visit www.keenova.com.
Overall, Keenova's presentation at the ACG Annual Meeting serves as a beacon of hope for patients and healthcare providers alike, signaling a brighter future for the management of HRS-AKI.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.